Lenz Therapeutics (LENZ) revenue and earnings history
Lenz Therapeutics reported revenue of $19.1M for fiscal 2025 (year ended Dec 31, 2025), and net income of −$82.1M.
Revenue and net income, 6 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $19.1M | −$91.1M | −$82.1M | −$69.2M | $827K | −$70M | $12.5M | — | — | $25.2M | — | 10-K |
| 2024ended Dec 31, 2024 | $0 |
The latest quarter, insider trades and fund moves: Lenz Therapeutics (LENZ) on OQRO.
Common questions
What was Lenz Therapeutics's revenue in fiscal 2025?
$19.1M for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 24, 2026.
Has Lenz Therapeutics been profitable?
It reported a net loss in 6 of the years shown (2020, 2021, 2022, 2023, 2024, 2025). The highest net income was −$49.8M in fiscal 2024.
What was Lenz Therapeutics's free cash flow in fiscal 2025?
−$70M: operating cash flow of −$69.2M minus capital expenditure of $827K. OQRO calculates free cash flow this way from the two filed lines.
Where these figures come from
The SEC’s companyfacts data: every figure Lenz Therapeutics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
